New York, Aug 5 : A single dose of a brand-new monoclonal antibody (mAb) has been shown to be completely safe and protective in adults exposed to malaria parasite, based on the results of the Phase 1 clinical trial.The mosquito that transmits malaria is the main illness which is brought on by Plasmodium parasites.
The World Health Organization estimates that in 2020, around 250 million people suffered from malaria, and around 627,700 of those died.
Scientists from the US National Institutes of Health were the ones who led the study of the mAb dubbed as L9LS, the laboratory-created version of an naturally occurring antibody known as L9 which is derived from the blood of an individual who was vaccinated with an experimental malaria vaccine.
The antibody stops malaria by neutralising parasites in the blood and on the skin before they infect liver cells.
“These early clinical trial findings showing that a monoclonal antibody given subcutaneously can help protect people from malaria are extremely positive,” said Anthony Fauci Director of National Institute of Allergy and Infectious Diseases (NIAID) which is which is a part of NIH.
“A one-time action that protects against malaria over a period of six months or a whole year could significantly decrease the rate of morbidity and mortality among children in areas with high malaria incidence and provide an effective tool to prevent malaria for health medical professionals or military personnel as well as travelers to these regions,” he added.
L9LS is similar to a potential anti-malarial antibody called CIS43LS which was developed by is a product of the National Institute of Health’s Vaccine Research Center (VRC) created and found to be extremely protective in small studies when administered via the intravenous route.
But, L9LS is two to three times more powerful.The increased potency allows for subcutaneous injections which is a more cost-effective and efficient method of administration than intravenous injection.
The study, which was published in The New England Journal of Medicine included 18 participants who received different dosages of L9LS either intravenously or subcutaneously.
After a few days of tolerantly receiving the injection and not having security concerns, the patients allowed mosquitoes that carried malaria parasites to bite their forearms five times.This began from 2 to 6 weeks following the injection of the mAb-related candidate in an environment that was carefully controlled.
L9LS completely protected fifteen of 17 (88 percent) individuals from malaria over the course of 21 days.
All participants in the group who did not receive L9LS were diagnosed with malaria and treated without any complications.It was encouraging to note that four of five volunteers who received a small dose, subcutaneous dose of the mAb, were protected from malaria.
“This is the first proof that a monoclonal antibody could protect when administered via the subcutaneous route with significant implications for clinical use and achieving the ultimate goal of elimination of malaria” stated Robert Seder the chief of the Cellular Immunology Section in the VRC who was the driving force behind the creation of L9LS.
Additional clinical trials to determine whether L9LS can help prevent malaria for six to twelve months against the perennial and seasonal transmission are currently underway in the infants and kids in Mali as well as Kenya where malaria is an issue.
rvt/
